These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 32223438)
1. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. Butler J; Anstrom KJ; Armstrong PW Circulation; 2020 Aug; 142(8):717-719. PubMed ID: 32223438 [No Abstract] [Full Text] [Related]
2. Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Lang NN; Dobbin SJH; Petrie MC Cardiovasc Res; 2020 Oct; 116(12):e152-e155. PubMed ID: 32980877 [No Abstract] [Full Text] [Related]
3. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW; Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546 [TBL] [Abstract][Full Text] [Related]
4. Vericiguat (Verquvo) for heart failure. Med Lett Drugs Ther; 2021 Mar; 63(1619):36-37. PubMed ID: 33755653 [No Abstract] [Full Text] [Related]
5. Dose-Finding Trials: Optimizing Phase 2 Data in the Drug Development Process. Viele K; Connor JT JAMA; 2015 Dec; 314(21):2294-5. PubMed ID: 26624828 [No Abstract] [Full Text] [Related]
6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136 [TBL] [Abstract][Full Text] [Related]
7. What can we learn from SOCRATES: more questions than answers? Cleland JGF; Mueller C Eur Heart J; 2017 Apr; 38(15):1128-1131. PubMed ID: 28204466 [No Abstract] [Full Text] [Related]
10. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J; JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152 [TBL] [Abstract][Full Text] [Related]
11. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Breitenstein S; Roessig L; Sandner P; Lewis KS Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610 [TBL] [Abstract][Full Text] [Related]
12. [Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)]. Bauersachs J; Nitschmann S Internist (Berl); 2020 Sep; 61(9):989-991. PubMed ID: 32591849 [No Abstract] [Full Text] [Related]
13. Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark? Coats AJS Eur J Heart Fail; 2020 Apr; 22(4):576-577. PubMed ID: 32115834 [No Abstract] [Full Text] [Related]
14. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B; JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357 [TBL] [Abstract][Full Text] [Related]
16. Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article 'Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial'. Aimo A; Castiglione V; Lombardi CM Eur J Heart Fail; 2020 Oct; 22(10):1934-1935. PubMed ID: 32353173 [No Abstract] [Full Text] [Related]
18. [Rosuvastatin has no effect on clinical outcomes in patients with heart failure. Results of the GISSI-HF trial]. Preorazhenskiĭ DV Kardiologiia; 2009; 49(4):64-5. PubMed ID: 19463122 [No Abstract] [Full Text] [Related]
19. Adenosine A1 receptor antagonists at a fork in the road. Givertz MM Circ Heart Fail; 2009 Nov; 2(6):519-22. PubMed ID: 19919975 [No Abstract] [Full Text] [Related]
20. Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat. Mehmood M JACC Heart Fail; 2021 Mar; 9(3):242. PubMed ID: 33632422 [No Abstract] [Full Text] [Related] [Next] [New Search]